119 related articles for article (PubMed ID: 35507889)
1. Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer.
Fonseca NM; Van der Eecken K; Herberts C; Verbeke S; Ng SWS; Lumen N; Ritch E; Murtha AJ; Bernales CQ; Schönlau E; Moris L; Van Dorpe J; Annala M; Wyatt AW; Ost P
JCO Precis Oncol; 2022 Apr; 6():e2100543. PubMed ID: 35507889
[TBL] [Abstract][Full Text] [Related]
2. Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
Nizialek E; Lim SJ; Wang H; Isaacsson Velho P; Yegnasubramanian S; Antonarakis ES
Prostate; 2021 Jun; 81(9):572-579. PubMed ID: 33955569
[TBL] [Abstract][Full Text] [Related]
3. Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype.
Shenderov E; Isaacsson Velho P; Awan AH; Wang H; Mirkheshti N; Lotan TL; Carducci MA; Pardoll DM; Eisenberger MA; Antonarakis ES
Prostate; 2019 Sep; 79(13):1572-1579. PubMed ID: 31389628
[TBL] [Abstract][Full Text] [Related]
4. Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review.
Van der Eecken K; Vanwelkenhuyzen J; Deek MP; Tran PT; Warner E; Wyatt AW; Kwan EM; Verbeke S; Van Dorpe J; Fonteyne V; Lumen N; De Laere B; Ost P
Eur Urol Oncol; 2021 Dec; 4(6):914-923. PubMed ID: 34801437
[TBL] [Abstract][Full Text] [Related]
5. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive Radical Prostatectomy for Metastatic Hormone-sensitive Prostate Cancer-Evidence from Recent Prospective Reports.
Rajwa P; Zattoni F; Maggi M; Marra G; Kroyer P; Shariat SF; Briganti A; Montorsi F; Heidegger I; Gandaglia G;
Eur Urol Focus; 2023 Jul; 9(4):637-641. PubMed ID: 36697321
[TBL] [Abstract][Full Text] [Related]
8. Targeted Next-Generation Sequencing Reveals Heterogenous Genomic Features in Viscerally Metastatic Prostate Cancer.
Gong Y; Fan L; Fei X; Zhu Y; Du X; He Y; Pan J; Dong B; Xue W
J Urol; 2021 Aug; 206(2):279-288. PubMed ID: 33780283
[TBL] [Abstract][Full Text] [Related]
9. Hormone naïve metastatic prostate cancer: How to treat it?
Østergren PB; Ternov KK; Jensen CFS; Jakobsen H; Lindberg H; Sønksen J; Fode M
Arch Esp Urol; 2019 Mar; 72(2):192-202. PubMed ID: 30855021
[TBL] [Abstract][Full Text] [Related]
10. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
Mager R; Savko O; Böhm K; Thomas A; Dotzauer R; Borgmann H; Jäger W; Thomas C; Haferkamp A; Höfner T; Tsaur I
Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168
[TBL] [Abstract][Full Text] [Related]
11. Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan.
Leith A; Ribbands A; Kim J; Clayton E; Gillespie-Akar L; Yang L; Ghate SR
BMC Urol; 2022 Mar; 22(1):33. PubMed ID: 35277153
[TBL] [Abstract][Full Text] [Related]
12. Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.
VanderWeele DJ; Finney R; Katayama K; Gillard M; Paner G; Imoto S; Yamaguchi R; Wheeler D; Lack J; Cam M; Pontier A; Nguyen YTM; Maejima K; Sasaki-Oku A; Nakano K; Tanaka H; Vander Griend D; Kubo M; Ratain MJ; Miyano S; Nakagawa H
Eur Urol Focus; 2019 May; 5(3):416-424. PubMed ID: 29398457
[TBL] [Abstract][Full Text] [Related]
13. The Genomics of Prostate Cancer: emerging understanding with technologic advances.
Rubin MA; Demichelis F
Mod Pathol; 2018 Jan; 31(S1):S1-11. PubMed ID: 29297493
[TBL] [Abstract][Full Text] [Related]
14. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
[TBL] [Abstract][Full Text] [Related]
15. Biopsy-detected Gleason grade 5 tumor is an additional prognostic factor in metastatic hormone-sensitive prostate cancer.
Lim B; Lee W; Kyung YS; You D; Jeong IG; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2022 Mar; 148(3):727-734. PubMed ID: 33948720
[TBL] [Abstract][Full Text] [Related]
16. Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer.
Hahn AW; Stenehjem DD; Alex AB; Gill DM; Cheng HH; Kessler ER; Chittoria N; Twardowski P; Vaishampayan U; Agarwal N
Urol Oncol; 2019 Jun; 37(6):352.e19-352.e24. PubMed ID: 30770300
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.
Wei L; Wang J; Lampert E; Schlanger S; DePriest AD; Hu Q; Gomez EC; Murakam M; Glenn ST; Conroy J; Morrison C; Azabdaftari G; Mohler JL; Liu S; Heemers HV
Eur Urol; 2017 Feb; 71(2):183-192. PubMed ID: 27451135
[TBL] [Abstract][Full Text] [Related]
18. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.
Sailer V; Schiffman MH; Kossai M; Cyrta J; Beg S; Sullivan B; Pua BB; Lee KS; Talenfeld AD; Nanus DM; Tagawa ST; Robinson BD; Rao RA; Pauli C; Bareja R; Beltran LS; Sigaras A; Eng KW; Elemento O; Sboner A; Rubin MA; Beltran H; Mosquera JM
Cancer; 2018 Mar; 124(5):1008-1015. PubMed ID: 29266381
[TBL] [Abstract][Full Text] [Related]
19. Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations.
Gandellini P; Casiraghi N; Rancati T; Benelli M; Doldi V; Romanel A; Colecchia M; Marenghi C; Valdagni R; Demichelis F; Zaffaroni N
Eur Urol Oncol; 2019 May; 2(3):277-285. PubMed ID: 31200842
[TBL] [Abstract][Full Text] [Related]
20. Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.
Fan L; Fei X; Zhu Y; Pan J; Sha J; Chi C; Gong Y; Du X; Zhou L; Dong B; Xue W
J Urol; 2021 Feb; 205(2):461-469. PubMed ID: 32897803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
